Topics

For Secondary Cardioprevention, Can We “Bridge” the Gap Between Evidence and Practice?

11:03 EDT 30 Apr 2019 | NEJM

A multifaceted intervention in Brazil improved prescription rates of guideline-recommended therapies, but clinical effects were less clear.

Original Article: For Secondary Cardioprevention, Can We “Bridge” the Gap Between Evidence and Practice?

NEXT ARTICLE

More From BioPortfolio on "For Secondary Cardioprevention, Can We “Bridge” the Gap Between Evidence and Practice?"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...